Monoclonal antibodies directed against the EGF receptor show differential bindings of amphiregulin and EGF to the EGF receptor

International Journal of Oncology

Volumn 10, Issue 2, 1997, Pages 339-347

  Modjtahedi, Helmout ^a   Cohen, Bruce D ^b   Dean, Christopher ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

amphiregulin; betacellulin; EGF receptor; epidermal growth factor; transforming growth factor

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BREAST CARCINOMA; CANCER CELL; CELL CULTURE; GENE EXPRESSION; HUMAN; HUMAN CELL; ISOTOPE LABELING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RECEPTOR BINDING;

EID: 0031051067     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.10.2.339     Document Type: Article

References (51)

1. Thompson DM and Gill GN: The EGF receptor: structure, regulation and potential role in malignancy. Cancer Surv 4: 767-788, 1985.
2. Carpenter G: Receptor for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56: 881-914, 1987.
3. Gullick WJ: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers.:Br Med Bull 47: 87-98, 1991.
4. Modjtahedi H and Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer (Review). Int J Oncol 4: 277-296, 1994.
5. Sporn MB and Roberts AB: Autocrine growth factors and cancers. Nature 313: 745-747, 1985.
6. Cohen S: Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal. J Biol Chem 237: 1555-1562, 1962.
7. Todaro GJ, De Larco JE and Cohen S: Transformation by murine and feline sarcoma viruses specifically blocks binding of epidermal growth factor to cells. Nature 264: 26-31, 1976.
8. Shoyab M, McDonald VL, Bradley G and Todaro GT: Amphiregulin: a bifunctional growth-modulating glycoprotein produced by the phorbol 12-myristate-treated human breast adenocarcinoma cell line MCF-7. Proc Natl Acad Sci USA 85: 6528-6532, 1988.
9. Higashiyama S, Abraham JA and Miller J: A heparin-binding growth factor secreted by macrophage-like cells that is related to EGF. Science 251: 936-939, 1991.
10. Shing Y, Christofori G and Hanahan D: Betacellulin: a mitogen from pancreatic β cell tumors. Science 259: 1604-1607, 1993.
11. Johnson GR, Prigent SA, Gullick WJ and Stromberg K: Characterization of high and low molecular weight forms of amphiregulin that differ in glycosylation and peptide core length. J Biol Chem 268: 18835-18843, 1993.
12. Toyoda H, Komurasaki T, Uchida D, Takayama Y, Isobe T, Okuyama T and Hanada K: Epiregulin, a novel epidermal growth factor with mitogenic activity for rat primary hepatocytes. J Biol Chem 13: 7495-7500, 1995.
13. Plowman GD, Green JM, McDonald VL, Neubauer MG, Disteche CM, Todaro GJ and Shoyab M: The amphiregulin gene encodes a novel epidermal growth factor-related protein with tumour-inhibitory activity. Mol Cell Biol 10: 1969-1981, 1990.
14. Shoyab M, Plowman GD and McDonald VL: Structure and function of human amphiregulin: a member of the epidermal growth factor family. Science 243: 1074-1076, 1989.
15. Johnson GR, Saeki T, Gordon AW, Shoyab M, Salomon DS and Stromberg KJ: Autocrine action of amphiregulin in a colon carcinoma cell line and immunocytochemical localization of amphiregulin in human colon. Cell Biol 118: 741-751, 1992.
16. Johnson GR and Wong L: Heparan sulfate is essential to amphiregulin-in̂duced mitogenic signaling by the epidermal growth factor receptor. J Biol Chem 269: 27149-27154, 1994.
17. crbB-2. J Biol Chem 268: 2924-2931, 1993.
18. Modjtahedi H, Styles J, Box G, Eccles S, Gusterson B and Dean C: Antitumour activity of rat mAbs to the human receptor for EGF. In: Mutant Oncogenes: Targets for Therapy? Epenetos AA and Lemonie NR (eds). Chapman Hall pp35-47, 1993.
19. Modjtahedi H, Styles J and Dean C: The human EGF receptor as a target for cancer therapy: six new monoclonal antibodies against the receptor on the breast carcinoma MDA-MB468. Br J Cancer 67: 247-253, 1993.
20. Modjtahedi H, Eccles S, Sandle J, Box G, Titley J and Dean C: Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the EGF receptor. Cancer Res 54: 1695-1701, 1994.
21. Modjtahedi H and Dean C: Antibody inhibition of EGFR over-expressing tumours occurs in the absence of receptor down-regulation. Int J Oncol 7: 783-788, 1995.
22. Modjtahedi H, Hichish T, Nicolson M, Moore J, Styles J, Eccles S, Jackson E, Salter J, Sloane J, Spencer L, Priest K, Smith I, Dean C and Gore M: A phase I trial and tumour localization of the anti-EGFR antibody 1CR62 in head and neck or lung cancer. Br J Cancer 73: 228-235, 1996.
23. Modjtahedi H and Dean C: The binding of HB-EGF to tumour cells is blocked by mAbs which acts as EGF and TGFα antagonists. Biochem Biophys Res Commun 207: 389-397, 1995.
24. Modjtahedi H and Dean C: Monoclonal antibody to the EGF receptor act as betacellulin antagonists. Biochem Biophys Res Commun 221:625-630, 1996.
25. Dean C, Modjtahedi H, Eccles S, Box G and Styles J: Immunotherapy with antibodies to the EGF receptor. Int J Cancer 8: 103-107,. 1994.
26. Cowley G, Smith JA, Gusterson B, Hendler F and Ozanne B: The amount of EGF receptor is elevated on squamous cell carcinomas. Cancer Cells 1: 5-10, 1984.
27. Filmus J, Pollak MN, Cailleau R and Buick RN: MDA-468, a human breast cancer cell line with a high number of epidermal growth factor EGF receptors, has an amplified EGF receptor gene and is growth inhibited by EGF. Biochem Biophys Res Commun 128: 898-905, 1985.
28. Kamata N, Kazuhiro C, Rikimaru K, Horikoshi M, Enomoto S and Kuroki T: Growth-inhibitory effects of epidermal growth factor and overexpression of its receptors on human squamous cell carcinomas in culture. Cancer Res 46: 1648-1653, 1986.
29. Ennis BW, Valverius EM, Bates SE, Lippman ME, Bellot F, Kris R, Schlessinger J, Masui H, Goldenberg A, Mendelsohn J and Dickson RB: Anti-epidermal growth factor receptor antibodies inhibit the autocrine-stimulated growth of MDA-468 human breast cancer cells. Mol Endocrinol 3: 1830-1838, 1989.
30. Modjtahedi H, Styles J and Dean C: The growth response of human tumour cell lines overexpressing the EGF receptor to treatment with EGF and/or mAbs that block ligand binding. Int J Oncol 3: 237-243, 1993.
31. Prigent SA and Lemoine NR: The type I EGFR-related family of growth factor receptors and their ligands. Prog Growth Factor Res 4: 1-24, 1992.
32. Wen D, Suggs SV, Karunagaran D, Liu N, Cupples RL, Luo Y, Jansen AM, Ben-Baruch N, Trollinger DB, Jacobson VL, Meng T, Lu HS, Hu S, Chang D, Yanigahara D, Koski RA and Yarden Y: Structural and functional aspects of the multiplicity of Neu differentiation factors. Mol Cell Biol 14: 1909-1919, 1994.
33. Yamamoto T, Ikawa S, Semba T, Nomura N, Miyajima N, Saito T and Toyoshima K: Similarity of protein encoded by the human c-erbB-2 gene to the epidermal growth factor receptor. Nature 319: 230-234, 1996.
34. King CR, Borrello I, Bellot F, Comoglio P and Schlessinger J: EGF binding to its receptor triggers a rapid phosphorylation of the c-erbE-2 protein in the mammary tumour cell line SKBR-3. EMBO J 7: 1647-1651, 1988.
35. Kraus MH, Issing W, Miki T, Popescu NC and Aaronson SA: Isolation and characterization of ERBB-3, a third member of the ERBB/epidermal growth factor receptor family: evidence for over-expression in a subset. Proc Natl Acad Sci USA 86: 9193-9197, 1989.
36. erbB-4, a fourth member of the epidermal growth factor receptor family. Proc Natl Acad Sci USA 90: 1746-1750, 1993.
37. Kim HH, Sierke SL and Koland JG: Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with erbB-3 gene product. J Biol Chem 269: 24727-24755, 1994.
38. Beerli RR, Graus-Porta D, Woods-Cook K, Chen X, Yarden Y and Hynes NE: Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15: 6496-6505, 1995.
39. Riese DJ, Bermingham Y, Raaij TM, Buckley S, Plowman GD and Stern DF: Betacellulin activates the epidermal growth factor receptor and erbB-4, and induces cellular response patterns distinct from those stimulated by epidermal growth factor and neuregulin-β. Oncogene 12: 345-353, 1996.
40. Beerli RR and Hynes NE: Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities. J Biol Chem 271: 6071-6076, 1996.
41. Le Jeune S, Leek R, Horak E, Plowman G, Greenall M and Harris AL: Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res 53: 3597-3602, 1993.
42. Yokoyama M, Ebert M, Funatomi H, Friess H, Buchler MW, Johnson GR and Korc M: Amphiregulin is a potent mitogen in human pancreatic cancer cells: correlation with patient survival. Int J Oncol 6: 625-631, 1995.
43. Modrcll B, McDonakd VL and Shoyab M: The interaction of amphiregulin with nuclei and putative localization sequence binding proteins. Growth Factors 7: 305-314, 1992.
44. Johnson GR, Saeki T, Auersperg N, Gordon AW, Shoyab M, Salomon DS and Stromberg K: Response to and expression of amphiregulin by ovarian carcinoma and normal ovarian surface epithelial cells: nuclear localization of endogenous amphiregulin. Biochem Biophys Res Commun 180: 481-488, 1991.
45. Schlessinger J and Ullrich A: Growth factor signaling by receptor tyrosine kinases. Neuron 9: 383-391, 1992.
46. Earp HS, Dawson TL, Li X and Yu H: Heterodimerization and functional interaction between EGF receptor family members: a new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat 35: 11-5-132, 1995.
47. Zhang K, Sun J, Liu N, Wen D, Chang D, Thomason A and Yoshinga S: Transformation of NIH 3T3 cells by HER3 and HER4 receptors require the presence of HER1 or HER2. J Biol Chem 271: 3884-3890, 1996.
48. Cohen BD, Green JM, Foy L and Fell HP: HER4-mediated biological and biochemical properties in NIH 3T3 cells. J Biol Chem 271: 4813-4818, 1996.
49. Martinez-Lacaci I, Saceda M, Plowman GD, Johnson GR, Normano N, Salomon DS and Dickson RB: Estrogen and phorbol esters regulate amphiregulin expression by two separate mechanisms in human breast cancer cell lines. Endocrinology 136: 3983-3992, 1995.
50. Adam R, Drummond DR, Solic N, Holt SJ, Sharma RP, Chamberlin SG and Davies DE: Modulation of the receptor binding affinity of amphiregulin by modification of its carboxyl terminal tail. Biochim Biophys Acta 1226: 83-90, 1995.
51. Thompson SA, Harris A, Hoang D, Ferrer M and Johnson GR: COOH-terminal extended recombinant amphiregulin with bio-activity comparable with naturally derived growth factor. J Biol 271: 17927-17931, 1996.